Showing 251-260 of 333 grants
| Title | Institution | Researcher | Program | Duration | Total Award Amount |
|---|---|---|---|---|---|
| A Novel Bifunctional Biologic for Type 1 Diabetes | Johns Hopkins University | Giorgio Raimondi | Cures | 01-February-2025 to 31-January-2028 | $995,376.00 |
| REGULATORY ROLE OF CADM1 DURING AUTOIMMUNE DIABETES | Johns Hopkins University | Matthew Poy | Cures | 01-December-2024 to 30-November-2027 | $900,000.00 |
| Towards FDA approval of Autonomous AI for diabetic retinopathy screening in youth | Johns Hopkins University | Risa Wolf | Improving Lives | 01-January-2023 to 31-December-2025 | $637,547.20 |
| Randomized Clinical Trial Evaluating Fenofibrate for Prevention of Diabetic Retinopathy Worsening | Jaeb Center for Health Research | Adam Glassman | Improving Lives | 01-February-2021 to 31-January-2026 | $750,000.00 |
| A Phase 2 Study Evaluating Short-Term Efficacy of Tonabersat (Xiflam) for Diabetic Macular Edema | Jaeb Center for Health Research | Adam Glassman | Improving Lives | 01-September-2022 to 01-January-2026 | $273,424.00 |
| JDRF T1D Coordinating Center | Jaeb Center for Health Research | Judy Sibayan | Transportfolio | 01-August-2019 to 31-August-2027 | $2,914,531.01 |
| Advanced Preclinical Development of iTOL-101, a Combination Investigational Product Composed of A Biotechnology-Derived Chimeric Streptavidin and A Fas Ligand (SA-FasL) Protein Bound to Biotinylated Hydrogel-Based Microparticles (Microgel) and Mixed with Deceased Donor Human Pancreatic Islets for the Treatment of Poorly-Controlled (or “Brittle”) Type 1 Diabetes | iTolerance, Inc. | Camillo Ricordi | Cures | 01-June-2022 to 31-August-2025 | $850,000.00 |
| JDRF-IQVIA Adult T1D Detection | IQVIA, Inc. | Nadejda Leavitt | Cures | 01-October-2022 to 31-August-2025 | $953,780.00 |
| Advancing T1D Detection and Care Through AI | IQVIA, Inc. | Nadejda Leavitt | Cures | 01-February-2025 to 31-January-2026 | $345,083.00 |
| Adult T1D Detection at Geisinger | IQVIA, Inc. | Nadejda Leavitt | Cures | 01-July-2023 to 31-December-2025 | $890,727.00 |